# Postoperative Head & Neck Radiation: Indications and Concurrent Chemotherapy

## Overview

Adjuvant radiation therapy (RT) following surgery for head and neck squamous cell carcinoma (HNSCC) plays a crucial role in reducing locoregional recurrence and improving survival, particularly in patients with adverse pathological features. Two landmark clinical trials, EORTC 22931 and RTOG 9501, have established the benefit of adding concurrent cisplatin chemotherapy to adjuvant RT in high-risk patients. The timing of adjuvant RT is critical; initiating treatment beyond six weeks after surgery is associated with poorer outcomes. Accurate target delineation in the postoperative setting requires careful integration of preoperative imaging, operative findings, and pathology reports to ensure appropriate coverage of at-risk areas.

## Indications for Adjuvant Radiation Therapy

### Standard Indications (RT Alone)

Adjuvant radiation therapy alone is typically indicated for patients with primary tumors classified as pT3 or pT4, nodal disease at stages N2 or N3, and those exhibiting perineural invasion (PNI) or lymphovascular invasion (LVI). Additionally, patients with close but negative surgical margins (less than 5 mm) and those with multiple positive lymph nodes without extranodal extension (ENE) are candidates for RT alone.

### Indications for Concurrent Chemoradiation

Concurrent chemoradiation is recommended in cases with positive surgical margins, defined as tumor cells at the inked margin, and extranodal extension, which is the most consistently validated indication for adding chemotherapy. The EORTC 22931 trial also included other high-risk features such as pT3 or pT4 tumors of the oral cavity or oropharynx, perineural invasion, lymphovascular invasion, and involvement of level IV-V lymph nodes from oral cavity or oropharynx primaries. A combined analysis of the EORTC 22931 and RTOG 9501 trials identified positive margins and ENE as the pathological features where concurrent cisplatin provides the greatest therapeutic benefit.

## Landmark Trials

### EORTC 22931 (Bernier et al., 2004)

This trial enrolled 334 patients with stage III-IV HNSCC involving the oral cavity, oropharynx, larynx, or hypopharynx. Patients were randomized to receive postoperative RT alone (66 Gy in 33 fractions) or postoperative RT combined with concurrent cisplatin chemotherapy (100 mg/m² every three weeks for three cycles). High-risk features included pT3 or pT4 tumors (except T3N0 larynx), positive surgical margins, extranodal extension, perineural invasion, lymphovascular invasion, and involvement of level IV-V lymph nodes from oral cavity or oropharynx primaries. The results demonstrated that chemoradiation improved five-year overall survival (53% vs. 40%, p=0.02), progression-free survival (47% vs. 36%, p=0.04), and locoregional control (82% vs. 69%, p=0.007).

### RTOG 9501 (Cooper et al., 2004)

This study included 459 patients with HNSCC and high-risk pathological features. Patients received postoperative RT (60-66 Gy) alone or combined with concurrent cisplatin (100 mg/m² every three weeks for three cycles). High-risk features were defined as two or more positive lymph nodes, extranodal extension, or positive surgical margins. The trial showed that chemoradiation improved two-year locoregional control (82% vs. 72%, p=0.01) and disease-free survival (hazard ratio 0.78, p=0.04). Although there was no statistically significant difference in overall survival at the initial report, long-term follow-up confirmed the persistence of locoregional control benefits.

### Combined Analysis (Bernier et al., 2005)

A joint analysis of the EORTC 22931 and RTOG 9501 trials revealed that the benefit of adding concurrent cisplatin chemotherapy was most significant in patients with positive surgical margins and extranodal extension. Other pathological features such as perineural invasion, lymphovascular invasion, and multiple positive nodes without extranodal extension showed less consistent benefit from chemotherapy addition.

| Trial | N | High-Risk Criteria | RT Dose | Chemo | Key Outcome (CRT vs. RT) |
|---|---|---|---|---|---|
| EORTC 22931 | 334 | pT3-4, +margins, ENE, PNI, LVI, level IV-V nodes | 66 Gy / 33 fx | Cisplatin 100 mg/m² q3wk x3 | 5-yr OS: 53% vs. 40% (p=0.02) |
| RTOG 9501 | 459 | ≥ 2 nodes, ENE, +margins | 60–66 Gy | Cisplatin 100 mg/m² q3wk x3 | 2-yr LRC: 82% vs. 72% (p=0.01) |
| Combined analysis | — | +Margins and ENE | — | — | Greatest cisplatin benefit for +margins and ENE |

## Radiation Therapy Technique

### Dose and Fractionation

For high-risk clinical target volumes (CTV), which include the tumor bed and involved nodal stations, the recommended dose is 60-66 Gy delivered in 30-33 fractions at 2 Gy per fraction. A boost dose of up to 66-70 Gy may be administered for positive margins. Elective nodal CTVs receive 54-56 Gy using a simultaneously integrated boost technique or 50 Gy in 25 fractions with a sequential technique. Ideally, radiation therapy should commence within six weeks of surgery, and the total "package time" from surgery to completion of RT should be within 11 weeks to optimize outcomes.

### Target Delineation in the Postoperative Setting

In the postoperative setting, there is no gross tumor volume (GTV) since the tumor has been resected; however, any areas of gross residual disease should be contoured if present. The high-risk CTV encompasses the surgical bed with an appropriate margin, guided by preoperative imaging, operative reports, and surgical clips, as well as positive nodal levels with extranodal extension. The elective CTV includes uninvolved nodal levels at risk based on the primary tumor site. Planning target volume (PTV) margins are institution-specific but typically range from 3 to 5 mm depending on image-guided radiation therapy (IGRT) capabilities. Surgical clips placed during resection are invaluable for delineating the high-risk CTV, and fusing preoperative imaging with the planning CT scan is essential for accurate target generation.

### IMRT/VMAT Considerations

Intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) is strongly preferred for postoperative head and neck RT to minimize xerostomia and dysphagia. Efforts should be made to spare the contralateral parotid gland, aiming for a mean dose below 26 Gy when feasible. Minimizing dose to the pharyngeal constrictor muscles is important to reduce dysphagia. Special attention is required to avoid hot spots on skin flaps used in reconstructive surgery, as excessive dose can increase the risk of wound breakdown.

## Concurrent Chemotherapy

### Cisplatin Regimens

The standard concurrent chemotherapy regimen consists of cisplatin administered at 100 mg/m² intravenously every three weeks for three cycles, typically on days 1, 22, and 43 of radiation therapy. An alternative regimen involves weekly cisplatin at 40 mg/m² for six to seven doses. Although no randomized trials have directly compared these dosing schedules in the postoperative setting, weekly cisplatin is commonly used in clinical practice due to better tolerability, despite the landmark trials employing the three-weekly high-dose regimen. The goal is to achieve a cumulative cisplatin dose of at least 200 mg/m².

### Toxicity Management

Grade 3 to 4 mucositis is common, especially when cisplatin is given concurrently with radiation. Nephrotoxicity is a significant concern with high-dose cisplatin, necessitating aggressive hydration protocols. Ototoxicity and peripheral neuropathy require baseline assessment and serial monitoring throughout treatment. For patients with oral cavity or oropharyngeal cancers receiving concurrent chemotherapy, prophylactic placement of a percutaneous endoscopic gastrostomy (PEG) tube should be considered to maintain nutrition during therapy.

## Special Considerations

### Timing of Radiation

Both the RTOG 9501 and EORTC 22931 trials mandated initiation of radiation therapy within six to eight weeks after surgery. Retrospective studies support that prolonged package time correlates with worse outcomes. Therefore, multidisciplinary coordination is essential to ensure timely wound healing and avoid surgical complications that could delay the start of radiation.

### Reconstructive Flaps and RT Planning

Free flap reconstructions, such as fibula, radial forearm, or anterolateral thigh flaps, should not delay radiation therapy. Target delineation must account for tissue rearrangement following flap reconstruction. Use of bolus material may be necessary for superficial targets but must be balanced against the risk of compromising flap viability.

### Unknown Primary with Cervical Node Metastasis

In cases of unknown primary presenting with cervical node metastasis, postoperative radiation therapy should cover the neck and potential mucosal sites, especially after neck dissection with extranodal extension or positive margins. Decisions regarding unilateral versus bilateral mucosal irradiation depend on the laterality and level of involved nodes. Human papillomavirus (HPV) or p16 status can guide mucosal target volumes, with palatine tonsil and base of tongue being key sites for HPV-positive disease.

<image>An annotated axial CT image at the level of the oropharynx showing postoperative target volume delineation. The high-risk CTV (red) encompasses the surgical bed with clips visible, the positive nodal station with extranodal extension. The elective CTV (blue) covers bilateral levels II-IV. Key organs at risk (parotid glands, spinal cord, pharyngeal constrictors) are outlined with their dose constraint labels.</image>

<image>A comparison table and flowchart summarizing the EORTC 22931 and RTOG 9501 trials. The top portion shows a side-by-side comparison of eligibility criteria, treatment arms, and key outcomes. The bottom portion is a clinical decision flowchart: starting from "Postoperative HNSCC" branching based on risk features (positive margins/ENE vs. other high-risk features vs. low-risk) to treatment recommendations (CRT vs. RT alone vs. observation).</image>

<image>A timeline graphic illustrating the concept of "package time" in postoperative head and neck treatment. The horizontal axis represents weeks from surgery (week 0) through completion of radiation (week 11-13). Key milestones are marked: wound healing assessment (week 2-3), RT simulation (week 4-5), RT start (week 5-6), and RT completion (week 11-13). A warning zone highlights delays beyond 6 weeks to RT start and package times exceeding 11 weeks as associated with inferior outcomes.</image>

## Key Clinical Pearls

The two pathological features that most consistently benefit from concurrent cisplatin chemotherapy are positive surgical margins and extranodal extension; these represent the undisputed indications for chemoradiation. The timing of therapy is critical, and coordination with surgical teams is necessary to ensure wound healing permits initiation of radiation within six weeks. The total package time, defined as the interval from surgery to completion of radiation, should ideally be under 11 weeks to optimize outcomes. In the postoperative setting, there is no gross tumor volume; instead, the high-risk clinical target volume is defined by the surgical bed, with accurate delineation relying on fusion of preoperative imaging to the planning CT. Placement of surgical clips at the time of resection is a vital multidisciplinary communication step that guides radiation oncologists in defining the target volume. Although landmark trials used high-dose cisplatin every three weeks, weekly cisplatin at 40 mg/m² is widely adopted in practice due to improved tolerability.

## References

- Bernier J et al. "Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer." *N Engl J Med*. 2004;350(19):1945-1952.  
- Cooper JS et al. "Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck." *N Engl J Med*. 2004;350(19):1937-1944.  
- Bernier J et al. "Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials." *Head Neck*. 2005;27(10):843-850.  
- Ang KK et al. "Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522." *J Clin Oncol*. 2014;32(27):2940-2950.  
- Graboyes EM et al. "Association of treatment delays with survival for patients with head and neck cancer: a systematic review." *JAMA Otolaryngol Head Neck Surg*. 2019;145(2):166-177.